[EN] A SUBSTITUTED OXOPYRIDINE DERIVATIVE<br/>[FR] DÉRIVÉ D'OXOPYRIDINE SUBSTITUÉ
申请人:BAYER PHARMA AG
公开号:WO2019197244A1
公开(公告)日:2019-10-17
The invention relates to 5-(6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2/7)-yl]-3-mcthylhcxanoyl}amino)pyrazolo[1,5-c/]pyridinc-3-carboxamide, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.
该发明涉及5-(6-氨基-2-[4-(5-氯-2-氰基苯基)-5-甲氧基-2-氧代吡啶-1(2/7)-基]-3-甲基己酰基}氨基)吡唑并[1,5-c/]吡啶-3-羧酰胺,其制备方法,其用于治疗和/或预防疾病的用途,以及用于制备用于治疗和/或预防疾病的药物的用途,特别是心血管疾病,优选是血栓性或血栓栓塞性疾病和水肿,以及眼科疾病,以及其用于抑制干扰性血浆激肽酶活性以进行体外程序和分析测定。